Skip to main content
Signal8
Launch Terminal

COMPASS Pathways plc (CMPS)

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

COMPASS Pathways plc logo

COMPASS Pathways plc

NASDAQ:CMPSHealthcare
-5.09%$11.57
AH$11.63+0.52%vs close
Mkt Cap$1.6B
Float127.2M
O/S138.48M
Vol
$ Vol
RVOL
Inst Own65.6%
Earnings
Dilution
COMPASS Pathways plc logoNASDAQ:CMPS$11.57-5.09%
Phase Distribution
9 lead-sponsored trials·3 active·6 completed
Phase 25
Phase 2/31
Phase 32
Not applicable1
(7 more as collaborator)
Status Overview
Recruiting1
Active, not recruiting2
Completed6

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

    Psilocybin

    Treatment Resistant Depression

    Enrollment
    258
    Start
    Jan 2023
    Primary Completion
    May 2025
    Completion
    Apr 2026
    NCT05624268
  • Phase 3
    Active, not recruiting

    Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

    Psilocybin

    Treatment Resistant Depression

    Enrollment
    572
    Start
    Feb 2023
    Primary Completion
    Nov 2025
    Completion
    Dec 2026est.
    NCT05711940
  • Phase 2/3
    Recruiting

    Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

    COMP360 psilocybin

    PTSD - Post Traumatic Stress Disorder, PTSD +2

    Enrollment
    300
    Start
    Sep 2026est.
    Primary Completion
    Nov 2028est.
    Completion
    Sep 2029est.
    NCT07570654
  • Phase 2
    Completed

    The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

    Psilocybin

    Treatment Resistant Depression

    Enrollment
    233
    Start
    Mar 2019
    Primary Completion
    Jul 2021
    Completion
    Sep 2021
    NCT03775200
  • Phase 2
    Completed

    The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

    Psilocybin

    Treatment Resistant Depression

    Enrollment
    19
    Start
    Aug 2020
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT04739865
  • Phase 2
    Completed

    The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

    Psilocybin

    Post Traumatic Stress Disorder

    Enrollment
    22
    Start
    Jun 2022
    Primary Completion
    Feb 2024
    Completion
    Feb 2024
    NCT05312151
  • Phase 2
    Completed

    Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

    Psilocybin

    Anorexia Nervosa

    Enrollment
    32
    Start
    Oct 2022
    Primary Completion
    Nov 2024
    Completion
    Nov 2024
    NCT05481736
  • Phase 2
    Active, not recruiting

    A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

    Psilocybin

    Major Depressive Disorder

    Enrollment
    102
    Start
    Jan 2023
    Primary Completion
    Sep 2025est.
    Completion
    Sep 2025est.
    NCT05733546
  • Observational
    Completed

    Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)

    -

    Treatment Resistant Depression

    Enrollment
    66
    Start
    Jul 2020
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT04519957
Search ClinicalTrials.gov for “COMPASS Pathways”